1. A method of administering glyburide to a subject, comprising intravenously administering to the subject over a period of time:
(a) a first bolus administration of glyburide;
(b) a second bolus administration of glyburide, after the first bolus; and
(c) a first continuous infusion administration of glyburide, wherein the first continuous infusion is administered at a first rate of administration for a first period of time, after the second bolus administration of glyburide.
2. The method of claim 1, further comprising a third bolus administration of glyburide.
3. The method of claim 1, wherein the first bolus administration delivers about 125 \u03bcg to about 150 \u03bcg glyburide.
4. The method of claim 1, wherein the second bolus administration delivers about 125 \u03bcg to about 150 \u03bcg glyburide.
5. The method of claim 1, further comprising a second continuous infusion administration of glyburide, wherein the second continuous infusion is administered at a second rate of administration for a second period of time.
6. The method of claims 1, wherein the rate of administration of the first continuous infusion is about 15 \u03bcghr and about 300 \u03bcghr.
7. The method of claim 1, wherein the period of time is about 1 hour to about 20 hours.
8. The method of claim 1, wherein the period of time is about 1 hour to about 10 hours.
9. The method of claim 1, wherein the period of time is about 1 hour to about 72 hours.
10. The method of claim 1, wherein the method is used to treat acute stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, hypoxiaischemia, or other injuries, conditions, and disorders.
11. The method of claim 1, further comprising a third bolus administration of glyburide and a second continuous infusion of glyburide, wherein the second continuous infusion is administered at a second rate of administration for a second period of time.
12. The method of claim 11, wherein the first rate and the second rate of administration for the first and second continuous infusions are each about 15 \u03bcghr and about 300 \u03bcghr.
13. The method of claim 1, wherein the total amount of glyburide administered during the administration is less than about 10 mg per day.
14. The method of claim 1, wherein the total amount of glyburide administered during the administration is less than about 6 mg per day.
15. The method of claim 1, wherein the total amount of glyburide administered during the administration is less than about 3.5 mg per day.
16. The method of claim 1, wherein the total amount of glyburide administered during the administration is less than about 3 mg per day.
17. A method of administering glyburide to a subject, comprising:
(a) a first bolus administration of glyburide;
(b) a first continuous infusion administration of glyburide after the first bolus administration of glyburide, wherein the first continuous infusion glyburide is administered at a first rate of administration for a first period of time; and
(c) a second continuous infusion administration of glyburide after the first continuous infusion of glyburide wherein in the second continuous infusion glyburide is administered at a second rate of administration for a second period of time;
wherein the glyburide is administered to the subject over a period of time.
18. The method of claim 17, wherein the first and second rate of administrations are each about 15 \u03bcghr and about 300 \u03bcghr.
19. The method of claim 17, wherein the total amount of glyburide administered during administration is less than about 10 mg per day.
20. The method of claim 17, wherein the total amount of glyburide administered during administration is less than about 6 mg per day.
21. The method of claim 17, wherein the total amount of glyburide administered during administration is less than about 3.5 mg per day.
22. The method of claim 17, wherein the total amount of glyburide administered during administration is less than about 3 mg per day.
23. The method of claim 17, wherein the first rate of administration is greater than the second rate of administration.
24. The method of claim 23, wherein the first period of time is about 1 hour to about 10 hours.
25. The method of claim 24, wherein the second period of time is a period of time of about 1 hour to about 10 hours.
26. The method of claim 17, wherein the method is used to treat acute stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, hypoxiaischemia, or other injuries, conditions, and disorders.
27. The method of claim 17, wherein the first continuous infusion has a rate of about 150 \u03bcghr to about 175 \u03bcghr of glyburide for a period of time of about 6 hours.
28. The method of claim 27, wherein the second continuous infusion has a rate of about 100 \u03bcghr to about 125 \u03bcghr glyburide.
29. The method of claim 28, wherein the second continuous infusion is administered over a period of time of about 66 hours, and where the sum of the first continuous infusion and of the second continuous infusion total a period of time of about 72 hours.
30. The method of claim 17, wherein the first bolus administration delivers about 125 \u03bcg to about 150 \u03bcg glyburide.
31. The method of claim 17, wherein the second bolus administration delivers about 125 \u03bcg to about 150 \u03bcg glyburide.
32. The method of claim 17, wherein the first continuous infusion administration has a rate of about 15 \u03bcghr to about 300 \u03bcghr glyburide.
33. The method of claim 17, wherein the second continuous infusion administration has a rate of about 15 \u03bcghr to about 300 \u03bcghr glyburide.
34. The method of claim 17, wherein the first bolus administration comprises administration of about 130 \u03bcg of glyburide followed by the first infusion of about 163 \u03bcghr glyburide for 6 hours followed by the second infusion of about 112 \u03bcghr glyburide for 66 hours.
35. The method of claim 17 further comprising:
(d) a third continuous infusion administration of glyburide, after the second continuous infusion of glyburide wherein the third continuous infusion of glyburide is administered at a third rate of administration for a third period of time.
36. The method of claim 35, wherein the period of time is about 1 hour to about 72 hours.
37. The method of claim 35, further comprising a second bolus administration of glyburide.
38. The method of claim 35, further comprising a fourth continuous infusion administration of glyburide wherein the fourth continuous infusion of glyburide is administered at a fourth rate of infusion for a fourth period of time.
39. The method of claim 35 further comprising both a second bolus administration of glyburide and a fourth continuous infusion administration of glyburide with a fourth rate of infusion for a fourth period of time.
40. The method of claim 35, wherein each rate of administration is about 15 \u03bcghr and about 300 \u03bcghr.
41. The method of claim 35, wherein each period of time is about 1 hour to about 72 hours.
42. The method of claim 35, wherein the total amount of glyburide administered during administration is less than about 10 mg per day.
43. The method of claim 35, wherein the total amount of glyburide administered during administration is less than about 6 mg per day.
44. The method of claim 35, wherein the total amount of glyburide administered during administration is less than about 3.5 mg per day.
45. The method of claim 35, wherein the total amount of glyburide administered during administration is less than about 3 mg per day.
46. The method of claim 35, wherein the method is used to treat acute stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, hypoxiaischemia, or other injuries, conditions, and disorders.
47. The method of claim 35, wherein each continuous infusion administration occurs on a separate day and the total daily dose of glyburide on Day 1, Day 2 and Day 3 is about 3 mg, 2.5 mg, and 2.5 mg respectively.
48. A method of administering glyburide, comprising:
(a) a first bolus administration of glyburide;
(b) a first continuous infusion administration of about 125 \u03bcghr to about 150 \u03bcghr glyburide after the first bolus administration of glyburide, wherein the first continuous infusion of glyburide is administered at a first rate of administration for a first period of time;
(c) a second continuous infusion administration of about 100 \u03bcghr to about 125 \u03bcghr glyburide after the first continuous infusion of glyburide, wherein the second continuous infusion of glyburide is administered at a second rate of administration for a second period of time;
(d) a third continuous infusion administration of glyburide after the second continuous infusion of about 15 \u03bcghr to about 300 \u03bcghr glyburide, wherein in the third continuous infusion of glyburide is administered at a third rate of administration for a third period of time; and
wherein the glyburide is administered to the subject over a period of time.
49. The method of claim 48, further comprising a second bolus administration of glyburide.
50. The method of claim 48, further comprising a fourth continuous infusion administration of glyburide at a fourth rate of infusion and a fourth period of time.
51. The method of claim 48, further comprising a second bolus administration of glyburide and a fourth continuous infusion administration of glyburide with a fourth rate of infusion for a fourth period of time.
52. The method of 48, wherein each period of time is about 1 hour to about 72 hours.
53. The method of claim 48 wherein the method is used to treat acute stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, or ventricular arrhythmias and wherein the amount of glyburide administered during administration is less than about 10 mg per day.
54. The method of claim 48, wherein the total amount of glyburide administered is less than about 6 mg per day.
55. The method of claim 48, wherein the total amount of glyburide administered is less than about 3.5 mg per day.
56. The method of claim48, wherein the total amount of glyburide administered is less than about 3 mg per day.
57. The method of claim 48, wherein the first rate of administration is greater than the second rate of administration.
58. The method of claim 57, wherein the first period of time is a period of time of about 1 hour to about 10 hours.
59. The method of claim 58, wherein the second period of time is a period of time of about 1 hour to about 10 hours.
60. The method of claim 48, wherein the first bolus administration comprises administration of glyburide over a period of time of about 3 minutes or less.
61. The method of claim 48, wherein the first bolus administration delivers about 125 \u03bcg to about 150 \u03bcg glyburide.
62. The method of claim 48, wherein the second continuous infusion is administered over a period of time of about 66 hours, whereby the sum of the periods of time of the first continuous infusion and of the second continuous infusion total about 72 hours.
63. The method of claim 48, wherein the method is used to treat acute stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, hypoxiaischemia, or other injuries, conditions, and disorders.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1.-11. (canceled)
12. A method for treating an optical lens, comprising:
providing an optical lens coated on at least one main surface thereof with a hydrophobic andor oleophobic external coating;
forming on at least part of the hydrophobic andor oleophobic external coating of the optical lens a temporary adhesive composite film, comprising a pre-formed film, one main surface of which adheres to a pressure-sensitive adhesive layer, the adhesive layer directly contacting the hydrophobic andor oleophobic coating;
recovering the optical lens comprising, in direct contact with at least part of the hydrophobic andor oleophobic coating, the temporary adhesive composite film adhering through the pressure-sensitive adhesive layer to the coated lens surface;
wherein the pre-formed film has a modulus of elasticity in tension E that is higher than or equal to 4200 MPa and a rupture stress of the temporary adhesive composite film bonded to a polycarbonate specimen coated with a fluorinated silane layer, measured under tensile stress in accordance with shear strength evaluation standard NF EN 1465, is higher than or equal to 0.05 MPa.
13. The method of claim 12, wherein the temporary adhesive composite film is applied onto at least one part of the hydrophobic andor oleophobic external coating of the optical lens, and the pre-formed film of the temporary adhesive composite film is further defined as a support film having a main surface coated with the pressure-sensitive adhesive layer prior to applying the temporary adhesive composite film.
14. The method of claim 12, wherein the pre-formed film modulus of elasticity in tension E\u2032 is higher than or equal to 4450 MPa.
15. The method of claim 14, wherein the pre-formed film modulus of elasticity in tension E\u2032 is higher than or equal to 4500 MPa.
16. The method of claim 12, wherein the rupture stress of the adhesive composite film bonded to a polycarbonate specimen coated with a fluorinated silane layer, measured under tensile stress in accordance with the shear strength evaluation standard NF EN 1465, is higher than or equal to 0.08 MPa.
17. The method of claim 16, wherein the rupture stress is higher than or equal to 0.1 MPa.
18. The method of claim 12, wherein the pre-formed film is a polyethylene terephthalate-based film or a cellulose triacetate-based film.
19. The method of claim 12, wherein the adhesive composite film has a thickness ranging from 1 to 250 \u03bcm.
20. The method of claim 19, wherein the adhesive composite film has a thickness ranging from 10 to 200 \u03bcm.
21. The method of claim 12, wherein the hydrophobic andor oleophobic coating has a thickness higher than or equal to 2 nm.
22. The method of claim 21, wherein the hydrophobic andor oleophobic coating has a thickness higher than or equal to 5 nm.
23. The method of claim 22, wherein the hydrophobic andor oleophobic coating has a thickness higher than or equal to 10 nm.
24. The method of a claim 12, wherein the hydrophobic andor oleophobic coating comprises fluorosilane andor fluorosilazane type materials.
25. The method of claim 12, wherein the temporary adhesive composite film is a coating that can be removed by stripping.
26. The method of claim 12, further comprising:
placing the optical lens in an edging device comprising a holding system comprising a holding element so that the holding element adheres to the external surface of the temporary adhesive composite film;
edging the lens;
discharging the lens out of the edging device; and
removing the adhesive composite film so as to recover an edged final optical lens.
27. An optical lens capable of being successfully edged, obtainable by a method of claim 12.